









2024 Spring ADRC Meeting

May 6-7, 2024, Austin, Texas

Sanjay Asthana, MD
Associate Dean for Gerontology
Director, Wisconsin Alzheimer's Disease Research Center
UW School of Medicine and Public Health, Madison, WI

NIH National Institute on Aging DESIGNATED Alzheimer's Disease Research Center

Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Disclosures

- I have received grants from NIA/NIH, Department of Veterans Affairs, State of Wisconsin, and UW-Madison to support my research program

  P30AG062715
  R01AG60737
  T32AG000213
  R24AG077433
  R01AG029624
  P50AG029624

- UW-Madison has received grants from pharmaceutical companies for me to serve as a site PI to conduct treatment trials involving patients with MCI and dementia
- I have no conflicts of interest for this presentation

Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Celebratory Historic Advances in Treatment of AD/ADRD Research

- Recent **approval of anti-amyloid monoclonal antibodies (MABs),** the first disease modifying treatments (DMTs) for MCI and early AD is monumental in AD therapeutics research
- In 2024, there are 164 active clinical trials assessing 127 dugs, including DMTs
- There are 23 studies [Phase 1 (6), Phase 2 (10), Phase 3 (7)] evaluating efficacy of drugs **targeting amyloid**
- 11 trials are evaluating efficacy of **anti-tau drugs**, including 4 in Phase 1, 6 in Phase 2, and 1 in Phase 3
- Four trials are evaluating efficacy of DMTs in **CU participants at risk for AD**, including AHEAD 3-45

Cummings, J et al, Alzheimer's Dement. 2024; 10:e12465

Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Treatment Advances for ADRD



Cummings, J et al, Alzheimer's Dement. 2024; 10:e12465

Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Treatment Advances for ADRD—Targeted Mechanisms



Cummings, J et al, Alzheimer's Dement. 2024; 10:e12465

Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Notable Advances in ADRD Research-Biomarkers

- Remarkable advances in the **discovery and validation of** multiple neuroimaging and fluid **AD/ADRD biomarkers** for:
  - Early detection and progression of AD pathology
  - Differentiation of AD from non-AD dementia
  - Response to treatments
  - Risk prediction
- Convincing evidence from autopsy series of multiple **co-existing pathologies** in decedents diagnosed with AD/ADRD. These pathologies include vascular damage, Lewy body disease, TDP-43, α-synuclein, LATE-NC, PART, ARTAG, etc.
- Concerted efforts to develop harmonized protocols for imaging and fluid biomarkers of co-existing pathologies and examine their impact on clinical phenotype, disease progression, treatment response, and mortality -**CLARiTI**



Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Notable Advances in ADRD Research

- Concerted focus on **health equity and disparities** research to better understand the neurobiology, clinical phenotype, & genetics of AD/ADRD in different races and ethnicities
- Enhanced community engagement to **diversify study cohorts** and **improve generalizability** of AD/ADRD research across the ADRC network
- Efforts to enhance generalizability through **Real World Data** collection from multiple sources, including EHR, cost and utilization data, public health data and patient-generated data



Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Overarching Scientific Themes

A) Non-amyloid mechanisms of AD/ADRD – TDP-43

B) Generalizability of AD/ADRD Research

- The scientific themes permeate nearly all the sessions of this 2-day meeting

Wisconsin Alzheimer's Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

TDP-43 Focused Presentations

A) Basic Biology of TDP-43

Speaker - Margaret Flanagan, MD

South Texas ADRC

B) Advances in Clinical Definitions and Biomarker Development for LATE

Speaker - David Wolk, MD

Penn ADRC

Generalizability Focused Presentations

A) Tackling the Landscape of Selection Bias and Representation in AD/ADRD Research: WHO We Study Matters

Speaker – Rachel Whitmer, PhD
UC Davis ADRC

B) Generalizability - Real World Data / EHR Focus

Speaker - Robert Califf, MD
Commissioner Food and Drugs, FDA